An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Takeda
- 22 Sep 2017 Planned End Date changed from 31 Jul 2018 to 31 Jan 2018.
- 22 Sep 2017 Planned primary completion date changed from 31 Jul 2018 to 31 Jan 2018.
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.